Beigene Ltd (BGNE) Director Donald W. Glazer Sells 36,443 Shares of Stock
Beigene Ltd (NASDAQ:BGNE) Director Donald W. Glazer sold 36,443 shares of the company’s stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $31.02, for a total transaction of $1,130,461.86. Following the transaction, the director now owns 4,881,997 shares of the company’s stock, valued at approximately $151,439,546.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Beigene Ltd (NASDAQ:BGNE) opened at 29.49 on Wednesday. Beigene Ltd has a 52-week low of $22.51 and a 52-week high of $35.60. The stock’s 50 day moving average is $29.73 and its 200 day moving average is $29.03. The company’s market cap is $970.31 million.
Beigene (NASDAQ:BGNE) last released its earnings results on Wednesday, August 10th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to analysts’ expectations of $2.08 million. The company’s revenue was down 71.4% on a year-over-year basis. Equities research analysts forecast that Beigene Ltd will post ($3.38) earnings per share for the current year.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research report on Friday, August 26th. Maxim Group assumed coverage on shares of Beigene in a research report on Wednesday, September 21st. They issued a “buy” rating and a $41.00 target price for the company. Finally, Cowen and Company reiterated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Beigene currently has an average rating of “Buy” and a consensus target price of $40.00.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. purchased a new stake in Beigene during the first quarter valued at approximately $112,000. Landscape Capital Management L.L.C. purchased a new stake in Beigene during the first quarter valued at approximately $202,000. Goldman Sachs Group Inc. purchased a new stake in Beigene during the first quarter valued at approximately $807,000. VHCP Management II LLC purchased a new stake in Beigene during the first quarter valued at approximately $3,488,000. Finally, Temasek Holdings Private Ltd purchased a new stake in Beigene during the first quarter valued at approximately $11,138,000.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Receive News & Stock Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related stocks with our FREE daily email newsletter.